Phase
Condition
Mood Disorders
Bipolar Disorder
Treatment
Level of Protein 14.3.3
Level of Proteins
Level of miR-451
Clinical Study ID
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
BD-1 as defined by DSM-5
Age : 18 to 70
Current treatment by lithium for more than one year
Euthymia defined by : MADRS <8 and YMRS <8 at inclusion ; no hospitalization orchange in mood-stabilizing treatment in the previous 3 months
Health condition compatible with blood and urinal sampling
Being affiliated to french social security
Written consent
Exclusion
Exclusion Criteria:
Treatment by : melatonin, agomelatin, benzodiazepines or hypnotic in the last 15days
Treatment by a strong CYP1A2 inducer in the last month : ciprofloxacine,dihydralazine, fluvoxamine, norfloxacine
Current substance use disorder except for tobacco
Chronic renal failure with glomerular filtration rate <60mL/min
Jetlag in the last 15 days or life-event impacting circadian rhythmicity (birth,grief, night-work...)
Sleep disorders such as Obstructive Sleep-Apnea, restless leg syndrome, narcolepsy
Pregnancy, breastfeeding
Guardianship
Inability to understand french, illiteracy
Study Design
Study Description
Connect with a study center
Hôpital Fernand-Widal
Paris, Ile De France 75010
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.